According to statistics, there are about 1.6 million new cancer patients in China each year, and the number of people who die from cancer every year is about 1.3 million. Among the many causes of death among residents of large and medium-sized cities in China, cancer is the first cause of death. The World Health Organization has made the latest authoritative conclusion that if cancer patients can find it early, the cure rate can reach more than 80%. Tumor markers can detect tumors earlier than imaging, and thus have profound implications for treating cancer. The secretion of tumor markers is derived from stromal cells of tumor microenvironment and tumor cells, which are present in cells, tissues or body fluids, and can be used to quantify the presence of tumors by chemical or immunological methods, and to monitor tumor treatment and prognosis. So far, no tumor markers with sensitivity and specificity of 100% have been found. The detection of single index and single factor is difficult to accurately achieve early detection of tumors, monitoring of disease duration and evaluation of prognosis treatment effects. As with the traditional Elisa method, only a single protein factor can be detected. To improve the accuracy and specificity of the assay, multiple Elisa assays are needed to detect different protein factors. Taking 10 protein factor assays as an example, 10 Elisa kits, at least 1 ml of sample, are needed for one week to get results. No matter whether it is human, financial or time and sample size, it is not a good choice. Moreover, the 10 factors are not detected at the same time and may also cause errors in the results. At present, one of the most convenient and efficient techniques for achieving joint detection of tumor markers is xMAP technology. The xMAP technology is based on different fluorescently encoded microbeads. Each of the coding beads is labeled with an antibody capable of capturing the corresponding target molecule, and 1-100 kinds of labeled beads are selected according to the number of detection targets, mixed and reacted with the target molecules to be tested in the sample, and then driven in the flow. Next, one by one through the detection window, two different wavelength lasers are used to detect each microsphere, the 635nm laser detects the color code of the microsphere to determine the detected target, and the 532nm laser detects the fluorescent label on the corresponding target for quantification, through computer analysis and Standard curve fitting directly quantifies each target molecule. The technology utilizes the Luminex multi-function liquid-chip platform to achieve multiple detection of target molecules such as proteins and nucleic acids. It is the only high-throughput technology that has been incorporated into the quality control of clinical laboratories in the United States. It is known as a true clinical biochip. Advantages of multiple detection platforms based on xMAP technology: At present, there are thousands of reports on the use of xMAP technology for the combined detection of tumor markers to improve the accuracy and specificity of tumor examination. For example, Irene et al. used a non-invasive method (serum) to detect six markers of ovarian cancer, and found that the combined diagnosis of the six markers was significantly higher than the original single CA-125 (95.3% vs 72%). This enables early treatment of ovarian cancer (Figure 2). As Luminex's first global partner, Merck offers a complete line of high-throughput multi-factor detection platforms including Luminex Instruments, Milliplex High-throughput Multi-Factor Detection Kit, Milliplex Analyst Software and Biomarker Service. Merck has been committed to multi-detection technology and research and development of biomarkers, with more than 30 years of research and development and service experience. At present, it can provide detection of more than 1200 protein factors in 8 species, involving many popular research fields such as immunity, metabolism, tumor, nerve, signal pathway and stem cell, which can meet the needs of development and diagnosis of most tumor markers. In addition, Merck has cooperated with cancer hospitals and research institutes across the country to provide testing platforms and services, and has accumulated 20 years of experience in testing and analysis. Therefore, it has opened a special application method for tumor markers, sharing successful experiences for clinical and diagnostic purposes. Research worker. This topic will be divided into multiple sessions to explore the multiple detection applications of markers for early detection of tumors, disease monitoring, mechanism studies, tumor metastasis and prognosis monitoring. Welcome to the Merck Biomarker Journal to keep abreast of the latest research. Scan QR code subscription topic
Our organic vegetable powder mainly used dehydration technology. Dehydration vegetable powder remained most fiber and taste of fresh vegetables, so they are suitable to be added in sauce, stuff, pudding, yogurt and dessert. Some vegetable powder could be applied as pigment like red beet root powder. Some could be mixed with other super green powders to make health formula, kale powder and broccoli powder are always good choice for customers.
Vegetable Powder,Red Beet Root Powder,Broccoli Powder,Organic Vegetable Powder YT(Xi'an) Biochem Co., Ltd. , https://www.ytwholefood.com
Figure 1: Common Tumor Marker Joint Detection Protocol 
Figure 2 The more the detection object is, the better the disease differentiation is (class represents the indicator classification, marker represents the specific indicator) 
Figure 3 Schematic diagram of xMAP technology
Video 1: Introduction to xMAP Technology and Milliplex Technology Platform
- Multiple detection: Simultaneous detection of 1-500 weight factors, providing technical support for accurate detection of trace samples;
- High sensitivity: Precision optical design improves detection sensitivity down to 0.04pg/ml;
- Fast/High Throughput: Automated high-throughput detection of 96/384-well plates with up to 9,600 results per hour;
- Trace sample: A sample size of only 10-50 ul is required to make it possible to track the phase changes of the animal model and avoid experimental errors caused by individual differences. 
Figure 4: Irene et al. Early detection of ovarian cancer has been published in Clinic Cancer Research (IF: 8.19) 